Managing research collaborations as a portfolio of contracts: a risk reduction strategy by pharmaceutical firms Online publication date: Sun, 06-Jul-2003
by Ganesh N. Prabhu
International Journal of Technology Management (IJTM), Vol. 18, No. 3/4, 1999
Abstract: This research proposes an empirically derived model of the process through which firms facing high R&D risks and costs, leverage their limited R&D resources, by contracting out upstream (laboratory scale) research at low cost for a portfolio of R&D projects to not-for-profit technology institutions. The firms then concentrate their limited R&D resources on downstream (commercial scale) R&D that utilises the limited set of successful upstream research outputs received from their collaborators. Small pharmaceutical firms that typically face both intense new product competition as well as high failure risks in upstream research adopt this risk reduction strategy. The process model has been developed by drawing from and synthesising in-depth project case studies of small pharmaceutical firms. Apart from contributing to the literature on managing technological collaboration, this model can enable practitioners in both firms and technology institutions to understanding effective processes for initiating and implementing this mutually beneficial risk reduction strategy.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technology Management (IJTM):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com